17 assets in Renal Pelvis/Ureter Urothelial Carcinoma

Therapeutic assets addressing Renal Pelvis/Ureter Urothelial Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cis-Diamminedichloroplatinum Ii Renal Pelvis/Ureter Urothelial Carcinoma	Nagoya University	P3	BBB (74)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Renal Pelvis/Ureter Urothelial Carcinoma	National Cancer Institute (NCI)	P2	BB (66)
Muamycin Renal Pelvis/Ureter Urothelial Carcinoma	UroGen Pharma Ltd.	P3	B (60)
Nivolumab Renal Pelvis/Ureter Urothelial Carcinoma	Nagoya University	P2	B (60)
Pembrolizumab Renal Pelvis/Ureter Urothelial Carcinoma	Dana-Farber Cancer Institute	P2	B (60)
st-02 Renal Pelvis/Ureter Urothelial Carcinoma	University of British Columbia	P2/3	B (57)
9mw2821 Renal Pelvis/Ureter Urothelial Carcinoma	Mabwell (Shanghai) Bioscience Co., Ltd.	P2	CCC (53)
Atezolizumab Renal Pelvis/Ureter Urothelial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Renal Pelvis/Ureter Urothelial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Tamivarotene Renal Pelvis/Ureter Urothelial Carcinoma	Nagoya University	P2	CCC (53)
Toripalimab Renal Pelvis/Ureter Urothelial Carcinoma	Mabwell (Shanghai) Bioscience Co., Ltd.	P2	CCC (53)
5-ala Renal Pelvis/Ureter Urothelial Carcinoma	Henry Ford Health System	P2	CCC (50)
Cabozantinib Renal Pelvis/Ureter Urothelial Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Cyclophosphamide Renal Pelvis/Ureter Urothelial Carcinoma	Beijing Biotech	P1	CC (43)
Eb-Dt-Nk-Uc101 Renal Pelvis/Ureter Urothelial Carcinoma	Beijing Biotech	P1	CC (43)
Fludarabine Renal Pelvis/Ureter Urothelial Carcinoma	Beijing Biotech	P1	CC (43)
Ipilimumab Renal Pelvis/Ureter Urothelial Carcinoma	National Cancer Institute (NCI)	P1	CC (43)